The Complete List of Research Peptides: A-Z Directory
How to use this list
This is an alphabetical-by-category reference for the research peptides and related compounds people search for most, including several Peptryn does not sell. Each entry gives a one-line identity, its current FDA status, and a link to Peptryn’s own guide or product page where one exists. Nothing here is dosing information. For how a certificate of analysis works, see what is a COA; for how research-use sales are treated, see our peptide legality guide; for a ranking of the most-searched compounds by volume, see popular peptides. FDA status is checked against public agency sources as of this writing and can change; verify before relying on it.
GLP-1 and metabolic peptides
| Compound | Identity | FDA status | Peptryn |
|---|---|---|---|
| Cagrilintide | Long-acting analogue of human amylin, developed by Novo Nordisk | Not approved on its own; filed Dec 2025 as part of the CagriSema combination, under review | Sold. Guide |
| Retatrutide | Investigational peptide (LY3437943), developed by Eli Lilly | Not approved; not yet filed, Lilly has said it plans to file in Q1 2027 | Sold. Guide |
| Semaglutide | Injectable, developed by Novo Nordisk | Approved as Ozempic (Dec 2017) and Wegovy (Jun 2021) | Not sold by Peptryn |
| Survodutide | Investigational peptide, licensed by Zealand Pharma to Boehringer Ingelheim | Not approved; FDA granted Breakthrough Therapy designation in Sept 2024, still in Phase 3 | Not sold by Peptryn |
| Tirzepatide | Injectable dual-incretin analogue, developed by Eli Lilly | The active compound in Mounjaro (May 2022) and Zepbound (Nov 2023) | Sold. Product page |
See our cagrilintide vs retatrutide comparison and retatrutide vs semaglutide and tirzepatide for how these compare on approval status.
Growth hormone axis peptides
| Compound | Identity | FDA status | Peptryn |
|---|---|---|---|
| CJC-1295 (no DAC) | Synthetic 29-amino-acid GHRH analogue (Modified GRF 1-29), about 3,368 Da | Not an approved drug | Sold. Guide |
| GHRP-6 | Growth hormone releasing hexapeptide | Not an approved drug in any major market; WADA-prohibited | Not sold by Peptryn |
| Ipamorelin | Synthetic pentapeptide, 711.85 Da, classed as a growth hormone secretagogue | Not an approved drug | Sold. Guide |
| Sermorelin | 29-amino-acid fragment of human GHRH, about 3,358 Da | Not currently approved; previously marketed as Geref, discontinued | Sold. Guide |
| Tesamorelin | Synthetic 44-amino-acid GHRH analogue, about 5,136 Da | The active compound in Egrifta, approved since 2010 | Sold. Guide |
CJC-1295 and ipamorelin are also sold and discussed together; see our CJC-1295 and ipamorelin guide.
Healing and regenerative peptides
| Compound | Identity | FDA status | Peptryn |
|---|---|---|---|
| AHK-Cu | Copper complex of the tripeptide Ala-His-Lys, about 354 Da as the peptide | Not an approved drug | Sold. Product page |
| BPC-157 | Synthetic 15-amino-acid peptide, 1,419.53 Da | Not an approved drug; WADA-prohibited (S0) | Sold. Guide |
| Glow Blend | Three-compound research blend: TB-500, BPC-157 and GHK-Cu | Not an approved drug; no component is approved for this use | Sold. Guide |
| GHK-Cu | Copper complex of the tripeptide Gly-His-Lys, about 340 Da as the peptide | Not an approved drug | Sold. Product page |
| Klow80 Blend | Four-compound research blend: TB-500, BPC-157, GHK-Cu and KPV | Not an approved drug; no component is approved for this use | Sold. Guide |
| KPV | Tripeptide Lys-Pro-Val, matching residues 11-13 of alpha-MSH, 342.44 Da | Not an approved drug | Sold. Product page |
| TB-500 | Full-length thymosin beta-4 acetate, 4,963.44 Da (the name is also used for a shorter fragment; check the certificate) | Not an approved drug; WADA S2 class | Sold. Guide |
| Wolverine Blend | Two-compound research blend: BPC-157 and TB-500 | Not an approved drug; no component is approved for this use | Sold. Guide |
For how these three blends actually differ, see any of the three guides above, each of which includes a component comparison table.
Mitochondrial and longevity peptides
| Compound | Identity | FDA status | Peptryn |
|---|---|---|---|
| Epitalon (Epithalon) | Synthetic tetrapeptide (Ala-Glu-Asp-Gly), developed at the Khavinson laboratory in St. Petersburg | Not an approved drug; a July 2026 FDA advisory committee recommended it for a compounding list, which is not approval | Not sold by Peptryn |
| MOTS-c | 16-amino-acid peptide encoded in mitochondrial DNA, about 2,175 Da | Not an approved drug | Sold. Guide |
| Pinealon | Synthetic tripeptide Glu-Asp-Arg, 418.40 Da, from the Khavinson bioregulator series | Not an approved drug | Sold. Product page |
| SS-31 (Elamipretide) | Synthetic tetrapeptide, 639.8 Da as the free base | The active compound in Forzinity, approved Sept 2025 | Sold. Guide |
Nootropic and cognitive peptides
| Compound | Identity | FDA status | Peptryn |
|---|---|---|---|
| Dihexa | Small-molecule peptidomimetic derived from angiotensin IV, developed at Washington State University | Not an approved drug; no published human trial, and its foundational papers were retracted in 2025 | Not sold by Peptryn |
| Selank | Synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), tuftsin-derived, 751.9 Da | Not FDA-approved; approved as a prescription nasal spray in Russia since 2011 | Sold. Guide |
| Semax | Synthetic heptapeptide derived from ACTH(4-7) | Not FDA-approved; approved in Russia since 1994; a July 2026 FDA advisory committee recommended it for a compounding list, which is not approval | Not sold by Peptryn |
Other compounds
| Compound | Identity | FDA status | Peptryn |
|---|---|---|---|
| 5-Amino-1MQ | Small molecule, not a peptide, 159.21 Da as the cation | Not an approved drug | Sold. Guide |
| AOD-9604 | Fragment of human growth hormone (176-191), developed in the 1990s in Australia | Not an approved drug; obesity trials failed their primary endpoint and development was discontinued in 2007 | Not sold by Peptryn |
| Glutathione | Tripeptide gamma-Glu-Cys-Gly, about 307 Da, present in most cells | Not an approved drug in this lyophilized research form | Sold. Guide |
| Kisspeptin-10 | C-terminal decapeptide of kisspeptin, a product of the KISS1 gene, about 1,302 Da | Not an approved drug | Sold. Product page |
| Melanotan-2 | Synthetic analogue of alpha-MSH | Not approved for any use anywhere; the FDA has issued warning letters against sellers since 2007 | Not sold by Peptryn |
| NAD+ | A dinucleotide coenzyme, not a peptide | Not an approved drug in injectable or research form | Not sold by Peptryn |
| PT-141 | Bremelanotide, an analogue derived from melanotan research | Approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women | Not sold by Peptryn |
| Thymosin Alpha-1 | 28-amino-acid thymic peptide | Not FDA-approved; approved as Zadaxin in more than 35 countries | Not sold by Peptryn |
How FDA status is grouped on this page
Three different situations get compressed into “not approved” online, and this list tries to keep them separate. Some compounds, like BPC-157, TB-500 and GHRP-6, have never been approved as a drug anywhere. Others, like tesamorelin and SS-31, are the identical active compound behind a separate, already-approved US drug sold under its own brand name. A few, like Selank, Semax and thymosin alpha-1, are approved prescription medicines in another country but have no FDA approval. An FDA advisory committee recommendation, like the one covering BPC-157, TB-500, KPV, Semax and Epitalon in July 2026, is a vote to consider adding a compound to a pharmacy-compounding list; it is not a drug approval, and the FDA is not bound by it.
What this means for research use
Peptryn supplies the compounds marked “Sold” above as lyophilized laboratory research materials only, not as the approved drugs, foreign-market products or combination products referenced in the FDA status column. We do not sell the compounds marked “Not sold by Peptryn,” and nothing on this page is dosing or administration guidance. See our guide to peptide legality for how research-use sales are treated, and what is a COA for how to check a lot before you order.
Common questions
Is this list complete?
No list of research peptides is ever complete; new compounds enter the research market regularly. This page covers the compounds most commonly searched for, verified against public sources at the time of writing, and it will be updated as facts change.
Does an FDA advisory committee recommendation mean a peptide is legal?
No. A recommendation to add a compound to a pharmacy-compounding list is advisory. It does not approve the compound as a drug, and it does not change how Peptryn or any other research supplier can sell it. See our peptide legality guide.
Why do some peptides show a different molecular weight elsewhere?
Several names on this list, most often “TB-500,” are used for more than one molecule by different sellers. Always check a listing’s own specification table and certificate of analysis rather than assuming a name means one fixed structure.
Related: Popular peptides by search volume · What is a COA? · Are peptides legal? · Peptide purity
For laboratory research use only. Not for human or veterinary use, and not a drug, food, dietary supplement or cosmetic. You must be 21 or older to buy.
